Thyrotrophynoma induced hyperthyroidism: what is the best management?

Helena Urbano Ferreira^{1,2}, Fernando Mendonça^{1,2}, Jorge Pedro^{1,2}, Celestino Neves^{1,2}, Sandra Belo¹, Davide Carvalho^{1,2}

¹Serviço de Endocrinologia, Diabetes e Metabolismo do Centro Hospitalar Universitário de São João,

² Faculdade de Medicina e Instituto de Investigação e Inovação Em Saúde da UP

- TSH-secreting pituitary adenomas are a rare cause of hyperthyroidism, accounting for < 1% of all cases of hyperthyroidism.
- TSH is usually normal or high; total and free T4 and T3 are high; in some cases plasma alpha subunit of glycoprotein hormones is elevated.
- Definitive therapy of TSH-secreting pituitary adenomas can be achieved through transsphenoidal resection of the tumor. The role of somatostatin analogs as a primary treatment requires further investigation.
- Medical therapy is used to restore euthyroidism prior to surgery. Typically, long-acting somatostatin analogs are used, but dopamine agonists are an alternative. Beta blockers are given to ameliorate the symptoms and signs of hyperthyroidism.







A 63-year old woman was sent to an Endocrinology appointment due to incidental thyroid nodules.

She had a history of hypertension, chronic gastritis and osteoporosis.

She was taking losartan, hydrochlorothiazide and omeprazol.

A few months earlier, she was medicated with bisoprolol due to complaints of palpitations. An EKG identified a sinus tachycardia.

She presented with no other symptoms of thyroid dysfunction.

INITIAL TESTING

TSH 3.97 uUI/L [0.35-4.94] Free T4 2.10 ng/dL [0.70-1.48] 个 Free T3 8.02 pg/mL [1.71-3.71] 个 TPO antibodies 0.5 UI/mL TRAbs <0.5 µUI/mL FSH 43.9 µIU/mL [25.8-34.8]

LH 28.3 µUI/mL [14.2-52.3] Prolactin 11.4 ng/mL [3.4-24.1] Morning serum cortisol 12.3 µg/mL [6.2-19.4] ACTH 11.2 pg/mL [<46] IGF-1 68.6 ng/ml [75-212]







He was taking bisoprolol, warfarin.

hydrochlorothiazide and lisinopril.



3. No response to TRH stimulation 4. Pituitary macroadenoma







Two patients with a history of a TSH-secreting adenoma were presented. The first patient had a microadenoma and was initially treated with octreotide LAR, with optimal response. After biochemical control of the hyperthyroidism, the patient underwent transsphenoidal surgery. The patient was euthyroid after surgery but the hyperthyroidism relapsed 2 months post surgery. She restarted treatment with octreotide LAR, again with an optimal and sustained response. The second patient had a macroadenoma and refused surgical treatment. He was treated solely with octreotide LAR, and also had an optimal and sustained response to medical treatment.

Although surgery is the definitive treatment for TSH-secreting adenomas, cure will only occur in one third of these individuals. Often, maintenance of euthyroidism depends on the use of medical therapy with somatostatin analogs, and medical management as a primary therapy can be an alternative.

